Study #2018-1090
A Phase 2 Study of Ixazomib and Rituximab in Bruton Tyrosine Kinase Inhibitor Resistant Mantle Cell Lymphoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Ixazomib, Ixazomib Citrate, Rituximab
Description
This phase II trial studies how well ixazomib and rituximab work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond (refractory) to BTK inhibitor treatment. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with rituximab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving ixazomib and rituximab may work better in treating patients with mantle cell lymphoma compared to rituximab alone.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Study phase:
Phase II
Physician name:
Hun Ju Lee
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-844-955-5036
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.